Clinical trials: Eczema/Atopic Dermatitis
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
ITCH, Atopic Dermatitis
Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical…
- Trial name
- NCT07560618
- Testing
- Roflumilast Cream 0.15%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Integrative Skin Science and Research
Atopic Dermatitis
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis
This study will describe safety of dupilumab in adult participants with atopic dermatitis. It will also look at the improvement of atopic dermatitis signs and symptoms in these participants.
- Trial name
- NCT07905547
- Testing
- Dupilumab
- Volunteers
- 56 people
- Sponsor
- Sanofi
Atopic Dermatitis
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT02176538
- Testing
- Product 0405
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Atopic Dermatitis (AD)
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07336940
- Testing
- ENV-294 Capsule
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Enveda Therapeutics
Dermatitis, Atopic
Protopic Ointment in Children Atopic Eczema
Children with atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks. They could continue during 3 more weeks once a day if needed.
- Trial name
- NCT00689832
- Testing
- Tacrolimus 0.03%, Fluticasone 0.005%
- Where
- France
- Volunteers
- 487 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
Primary objective: To evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS) compared with placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).
- Trial name
- ECZTRA 8 (NCT04587453)
- Testing
- Tralokinumab, Topical corticosteroids (TCS)
- Where
- 25 sites in Japan
- Volunteers
- 106 people
- Sponsor
- LEO Pharma
Atopic Disorders, Eczema, Atopic
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).
- Trial name
- NCT03050151
- Testing
- Dupilumab, Auto-injector Device, Prefilled syringe
- Where
- 37 sites in United States
- Volunteers
- 176 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Psoriasis
Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and Psoriasis
Pruritis is a common symptom in patients with atopic dermatitis and psoriasis. Patients with atopic dermatitis and psoriasis often report pruritis-associated sleep impairments and scratching behaviors during nighttime and the…
- Trial name
- DECODE-Scratch (NCT06448689)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- ActiGraph L.L.C
Atopic Dermatitis
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADmIRe (NCT03831191)
- Testing
- LY3375880
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 136 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
- Trial name
- PROSE (NCT03428646)
- Testing
- Dupilumab
- Where
- 99 sites in United States, Canada
- Volunteers
- 858 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Evaluation and Comparison of 2 Cosmetic Investigational Products in Adults With Atopic Dermatitis
The study consists in the application of 2 investigational products (one group per investigational product) under normal conditions of use, in adult participants with Atopic Dermatitis.
- Trial name
- NCT03632174
- Testing
- Topical Ointment with L. reuteri, Topical Ointment without L. reuteri
- Where
- South Africa
- Volunteers
- 36 people
- Sponsor
- BioGaia AB
Dermatitis, Atopic
Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study was to evaluate the safety and tolerability of 611 in chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT05641558
- Testing
- 611 150mg, 611 300mg, 611 600mg
- Where
- 5 sites in China
- Volunteers
- 24 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Hidradenitis Suppurativa, Dermatitis, Atopic
Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis
This non-intervention study will identify the biomarker profiles in hidradenitis suppurativa (HS) and atopic dermatitis (AD) (as a comparator) that would have the most utility in interventional studies evaluating efficacy during…
- Trial name
- NCT04440410
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Kymera Therapeutics, Inc.
Atopic Dermatitis
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in…
- Trial name
- NCT04562116
- Testing
- Nemolizumab, CYP 450 Substrates
- Where
- 6 sites in United States, Bulgaria
- Volunteers
- 17 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis
Purpose of the study: One bothering feature of atopic dermatitis is its relapsing nature. Hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until the disease recurs.
- Trial name
- NCT00185510
- Testing
- Methylprednisolone Aceponate (Advantan, BAY86-4862)
- Volunteers
- 250 people
- Sponsor
- LEO Pharma
Healthy Participants, Healthy Subjects
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
This study is the first-in-human (FIH) study of BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035 with both a single dose and multiple doses administered at different…
- Conditions
- Healthy Participants, Healthy Subjects, Healthy Volunteers, Autoimmune Diseases
- Trial name
- NCT06342713
- Testing
- BGB-45035
- Where
- 13 sites in Australia, China and 1 more
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- BeiGene
Atopic Dermatitis
Use of a Mobile Health App in Managing Pediatric Atopic Dermatitis
A randomized controlled study in children with AD, divided into three groups: a control group without access to the app, an experimental observational group with the app, and an experimental interventional group with potential…
- Trial name
- NCT06412094
- Testing
- Standard care, Access to the "AtopicApp" mobile application, Virtual oversight through the AtopicApp
- Where
- Russia
- Volunteers
- 66 people
- Sponsor
- Avanta Trading Ltd.
Dermatitis, Atopic
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4…
- Trial name
- NCT02001181
- Testing
- Tofacitinib ointment 20mg/g
- Where
- 5 sites in Canada
- Volunteers
- 69 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.